Merck Sharp & Dohme LLC × Parkinsons
Merck Sharp & Dohme LLC parkinsons: 7 indexed trials, 3 recruiting studies across 1 countries in the current NeuroRisk corpus.
Request comparative brief →Indexed trials7
Recruiting3
Countries1
Indexed studies
NCT03765918Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)
United StatesPHASE3
United StatesPHASE3
NCT00505843A Study of MK0657 in Parkinson's Disease Patients (0657-006)
PHASE1
PHASE1
NCT04305054Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)
United StatesPHASE1,PHASE2
United StatesPHASE1,PHASE2
NCT01294800A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)
PHASE2
PHASE2
NCT06036836Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
United StatesPHASE2
United StatesPHASE2
NCT05239728A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
United StatesPHASE3
United StatesPHASE3
NCT07252739KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
United StatesPHASE2
United StatesPHASE2
Enterprise comparison
Compare sponsor momentum, recruiting activity, geography and connected evidence with the broader NeuroRisk intelligence layer.
Request enterprise access →